Melichar B, Malír F, Jandík P, Malírová E, Vávrová J, Mergancová J, Voboril Z
Second Department of Internal Medicine, Charles University Medical School, Hradec Králové, Czech Republic.
Biometals. 1995 Jul;8(3):205-8. doi: 10.1007/BF00143377.
Urinary zinc excretion is known to be increased in cancer patients, but the pathogenesis of this phenomenon remains uncertain. Both skeletal muscle catabolism and renal tubular cell dysfunction have been proposed to explain this observation. We have investigated urinary zinc and N-acetyl-beta-D-glucosaminidase (NAG), an indicator of renal tubular cell dysfunction, as well as serum neopterin, an index of systemic immune activation, in 22 patients with cancer and seven controls. Both serum neopterin and urinary zinc were significantly elevated in cancer patients (15.8 +/- 12.7 versus 7.3 +/- 2.3 nmol l-1 and 1.77 +/- 0.80 versus 1.21 +/- 0.41 mmol mol-1 creatinine, P < 0.02 and P < 0.05, respectively), while NAG was similar in cancer patients and the controls (13.58 +/- 13.80 versus 13.68 +/- 12.19 mu kat mol-1 creatinine). A significant correlation was observed between serum neopterin and urine zinc (rs = 0.5119, P < 0.02), serum neopterin and urine NAG (rs = 0.6761, P < 0.002), and urinary zinc and NAG (rs = 0.6348, P < 0.002). In conclusion, the present data indicate a link between urinary zinc excretion and immune activation as well as renal tubular cell dysfunction. In addition, renal tubular cell dysfunction appears to be linked to immune activation.
已知癌症患者的尿锌排泄量会增加，但这种现象的发病机制仍不确定。有人提出骨骼肌分解代谢和肾小管细胞功能障碍来解释这一现象。我们研究了22例癌症患者和7名对照者的尿锌和N - 乙酰 - β - D - 氨基葡萄糖苷酶（NAG，肾小管细胞功能障碍的指标），以及血清新蝶呤（全身免疫激活的指标）。癌症患者的血清新蝶呤和尿锌均显著升高（分别为15.8±12.7对7.3±2.3 nmol l-1和1.77±0.80对1.21±0.41 mmol mol-1肌酐，P < 0.02和P < 0.05），而癌症患者和对照者的NAG相似（13.58±13.80对13.68±12.19 mu kat mol-1肌酐）。血清新蝶呤与尿锌（rs = 0.5119，P < 0.02）、血清新蝶呤与尿NAG（rs = 0.6761，P < 0.002）以及尿锌与NAG（rs = 0.6348，P < 0.002）之间均观察到显著相关性。总之,目前的数据表明尿锌排泄与免疫激活以及肾小管细胞功能障碍之间存在联系。此外,肾小管细胞功能障碍似乎与免疫激活有关。
